Abstract

SO.11.07

Intravitreal Bevacizumab as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia

Dithmar S., Schaal K. B., Höh A. E., Schütt F.
Department of Ophthalmology, University of Heidelberg

Objective: To evaluate the safety and efficacy of intravitreal bevacizumab as treatment for subfoveal choroidal neovascularisation (CNV) due to pathological myopia.
Methods: Consecutive series of patients with primary (n=10) or recurrent (n=2) subfoveal CNV secondary to myopia were treated with intravitreal bevacizumab 1,25mg after being thoroughly informed about the off-label character of the treatment. 9 patients received bevacizumab treatment only, 3 patients additional photodynamic therapy at the time of first injection. Visual acuity (EDTRS), ophthalmic examination and OCT were performed at baseline and at 6-week intervals. Fluorescein-angiography was performed depending on the clinical and OCT-findings. Reinjections were given every 6 weeks if intra- or subretinal fluid persisted.
Results: Pre-injection mean visual acuity measured 0,25 (0,59 logMAR±0,22). During a follow-up of 16±11 weeks 1,6±0,8 injections were given. 3 eyes received 3 injections, one eye two and 8 eyes only one injection. Complete resorption of sub- or intraretinal fluid and inactivation of CNV shown by angiography was achieved in all patients. Visual acuitiy (VA) improved by a mean of 1,7±2,4 lines. 7 eyes showed improvement of VA, 3 eyes had unchanged VA and 2 eyes lost 1 and 3 lines, respectively, the latter due to subfoveal hemorrhage. No intraocular or systemic side effects were observed.
Conclusions: In this series intravitreal bevacizumab seems to be efficacious in eyes with subfoveal CNV secondary to pathological myopia.

Copyright: Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.